Keytruda significantly improved PFS compared with brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma. - Merck Inc.
Related news and insights
NICE (UK): Pembrolizumab is recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older.
Seagen Inc. announced that the phase III ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival (OS) (p=0.009) in patients with advanced classical Hodgkin lymphoma (cHL) following treatment with Adcetris (brentuximab vedotin) in combination with chemotherapy.
Akeso, Inc. announced that the anti PD-1 monoclonal antibody drug penpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited has obtained marketing approval by the National Medical Products Administration (the “NMPA”) of China, for treatment of patients with relapsed or refractory (“r/r”) classic Hodgkin’s lymphoma (“cHL”) after at least second-line systemic chemotherapy treatment.